A Systematic Approach to HIV-1 Vaccine Immunogen Selection
- 1 September 2020
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 36 (9) , 762-770
Abstract
A tremendous loss of financial and human resources from seven large-scale HIV vaccine efficacy trials suggest a need for a systematic approach to vaccine selection. We conducted a systematic analysis of three important Env vaccine candidates: BG505 SOSIP.664, 1086.C gp140 and 1086.C gp120 to determine the most promising by comparing their structure and antigenicity. We found that the BG505 SOSIP trimer and 1086.C gp140 clearly outperformed the 1086.C gp120 monomer. BG505 SOSIP.664 bound the strongest to the most potent and broadest bnAbs PG9, PGT145, VRC01 and PGT121. Interestingly, while BG505 SOSIP.664 did not bind to the CH58 mAb, 1086.C gp140 bound strongly to this mAb, which belongs to a class of non-neutralizing antibodies that may be protective based on correlates of protection studies of the RV144 HIV vaccine trial. The 1086.C gp120 monomer was the least antigenic of the three vaccine immunogens, binding the weakest to bnAbs and CH58 mAb. Taken together, the evidence provided here combined with previous preclinical immunogenicity and efficacy data strongly argue that the BG505 SOSIP.664 trimer and 1086.C gp140 are likely to be better vaccine immunogens than the monomeric 1086.C gp120, which was just recently tested and shown to be non-efficacious in a phase IIb/III trial. Thus, to best utilize our financial and valuable human resources, we propose a systematic approach by not only comparing structure and antigenicity, but also immunogenicity and efficacy of Env vaccine candidates in the preclinical phase to the selection of only the most promising vaccine candidates for clinical testing.Keywords
This publication has 45 references indexed in Scilit:
- Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9Proceedings of the National Academy of Sciences, 2013
- Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoProceedings of the National Academy of Sciences, 2012
- HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120Proceedings of the National Academy of Sciences, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyThe Lancet Infectious Diseases, 2011
- Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cellsJournal of Virological Methods, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1Molecular Immunology, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008